Retatrutide skin side effects are an important consideration for patients and clinicians following this investigational triple incretin receptor agonist through its Phase 3 clinical trials. As a GLP-1, GIP, and glucagon receptor agonist being evaluated for obesity and type 2 diabetes, retatrutide shares some skin-related adverse effects with other subcutaneous incretin therapies, whilst its full dermatological profile remains under investigation. This article outlines the skin reactions reported to date, who may be at greater risk, how to manage symptoms effectively, when to seek medical advice, and the current MHRA regulatory position on retatrutide in the UK.

Skin Side Effects Reported with Retatrutide

The most consistently reported retatrutide skin side effects are injection site reactions — including redness, swelling, bruising, and itching — with hair thinning and generalised rash also noted in some trial participants.

Retatrutide is an investigational triple incretin receptor agonist that targets the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors simultaneously.^[1][2] It is currently being evaluated in Phase 3 clinical trials for the management of obesity and type 2 diabetes.^[2] As with other agents in the incretin class, a range of side effects has been observed during trials, including some affecting the skin.

The most consistently reported skin-related side effect associated with retatrutide is injection site reactions. These include:

• Localised redness (erythema)

• Swelling or induration at the injection site

• Bruising or haematoma formation

• Itching (pruritus) around the injection area

• Mild pain or tenderness following administration

These reactions are broadly consistent with those seen with other subcutaneously administered incretin therapies. For reference, the UK Summaries of Product Characteristics (SmPCs) for semaglutide (Wegovy) and tirzepatide (Mounjaro) both list injection site reactions — including erythema, pruritus, and bruising — as recognised adverse effects of their respective drug classes.^[5]

Beyond injection site effects, some trial participants have reported more generalised skin symptoms, including diffuse pruritus and, in isolated cases, rash. The incidence and severity of these generalised reactions have not yet been fully characterised, as retatrutide's full adverse event profile is still being established through ongoing trials.

Hair thinning has also been noted in the context of significant rapid weight loss associated with GLP-1-based therapies. It is important to note that alopecia is listed as an adverse reaction in the SmPCs of some licensed GLP-1 receptor agonists (for example, semaglutide).^[5] Whether hair shedding associated with retatrutide reflects a direct pharmacological effect, an indirect consequence of caloric restriction and rapid weight loss (telogen effluvium), or both, remains uncertain. Patients experiencing hair thinning should discuss this with their clinician.

Retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA). The full skin side effect profile is still being characterised, and all data available at this time are preliminary. The primary published evidence base includes the Phase 2 randomised controlled trial reported by Jastreboff et al. in the New England Journal of Medicine (2023).

How Common Are These Reactions and Who Is at Risk

Injection site reactions were among the more common adverse events in Phase 2 trials, generally mild to moderate; those not rotating sites, on anticoagulants, or with allergic skin conditions may be at greater risk.

Based on Phase 2 trial data (Jastreboff et al., NEJM 2023), injection site reactions with retatrutide were among the more commonly reported adverse events, occurring across multiple dose groups. They were generally described as mild to moderate in severity and transient in nature. Serious or severe skin reactions were infrequent in the trial populations studied to date. Precise incidence figures varied by dose and are subject to revision as Phase 3 data accumulate; patients and clinicians should refer to the most current published trial results and, once available, the approved SmPC.

Certain individuals may be at greater risk of experiencing skin side effects. Based on general principles applicable to subcutaneous injectable therapies:

• Those who do not rotate injection sites adequately, leading to repeated trauma to the same area

• Individuals on concomitant anticoagulant therapy (for example, warfarin or direct oral anticoagulants), who may experience more pronounced bruising

• People with a history of allergic skin conditions, who may be more prone to localised irritation, though this has not been specifically studied for retatrutide

It should be noted that risk factors relating to specific excipients or the effect of body mass index on injection site reactions cannot be confirmed at this stage, as retatrutide's final formulation details are not yet publicly available in a licensed SmPC.

The risk of generalised skin reactions, such as widespread rash or urticaria, appears to be low based on current evidence, though trial populations may not fully reflect the diversity of patients who would use the medication in routine clinical practice.

Regarding hair thinning: rapid weight loss can trigger telogen effluvium, a temporary form of diffuse hair shedding that typically resolves spontaneously within several months once weight stabilises.^[4] However, as noted above, alopecia has been reported with some licensed GLP-1 receptor agonists, and the precise contribution of the drug versus weight loss to hair shedding with retatrutide remains uncertain. Patients experiencing significant or persistent hair loss should seek clinical review.

Managing Skin Symptoms During Treatment

Rotating injection sites, using a fresh needle each time, and allowing the solution to reach room temperature are the most effective measures; mild pruritus may be relieved with a cool compress or oral non-sedating antihistamine.

For most people, skin side effects associated with retatrutide are manageable with straightforward practical measures. Proper injection technique is the single most important factor in minimising localised reactions. Healthcare professionals should ensure patients receive thorough training before self-administering the medication, and patients should follow the product's instructions for use carefully.

Key injection site management strategies include:

• Rotating injection sites systematically — for example, alternating between the abdomen, thigh, and upper arm — to prevent repeated trauma to the same area

• Allowing the medication to reach room temperature before injection, in accordance with the product's storage instructions, as cold solutions can increase discomfort and local tissue irritation

• Using a new needle for each injection to maintain sharpness and reduce tissue damage

• Applying gentle pressure (but not rubbing) to the injection site after administration to minimise bruising

• Keeping the skin clean and dry around injection sites to reduce the risk of secondary infection

• Avoiding injection into broken, irritated, or infected skin

For mild pruritus or erythema at the injection site, a cool compress applied for a few minutes post-injection can provide symptomatic relief. For persistent localised itching or mild inflammation, an oral non-sedating antihistamine (such as cetirizine or loratadine, available over the counter) or a short course of 1% hydrocortisone cream applied to the affected area may be appropriate — patients should seek advice from a pharmacist or clinician before using any additional treatments. Topical antihistamine creams are not recommended for this purpose, as they carry a risk of contact sensitisation and are not supported by UK clinical guidance (BNF; NICE CKS).^[9]

In the context of hair thinning, ensuring adequate nutritional intake is advisable, particularly of protein, iron, zinc, and B vitamins (such as B12 and folate). A balanced diet remains important even during caloric restriction. Routine supplementation with biotin is not recommended, as evidence for its benefit in telogen effluvium is limited, and high-dose biotin can interfere with certain laboratory tests (including thyroid function tests and troponin assays), potentially producing misleading results — an issue highlighted in MHRA Drug Safety Update guidance.^[7] If patients are already taking biotin supplements, they should inform their clinician.

Patients experiencing significant hair shedding should discuss this with their prescribing clinician, who may recommend blood tests to exclude nutritional deficiencies (iron, B12, folate, zinc) or thyroid dysfunction as contributing factors.

When to Seek Medical Advice from Your GP, Specialist, or Trial Team

Seek prompt medical advice for spreading rash, urticaria, or facial swelling; call 999 immediately if breathing is affected, as this may indicate anaphylaxis.

Whilst most skin side effects associated with retatrutide are mild and self-limiting, there are specific circumstances in which patients should seek prompt medical advice. Recognising the warning signs of a more serious reaction is an important aspect of patient safety.

Contact your GP, specialist, or clinical trial team promptly if you experience:

• A spreading rash, hives (urticaria), or widespread skin redness that develops after starting treatment

• Swelling of the face, lips, tongue, or throat, which may indicate angioedema — a potentially serious allergic reaction requiring urgent assessment

• Difficulty breathing or swallowing alongside skin changes — call 999 immediately, as this could indicate anaphylaxis

• Signs of infection at an injection site, including increasing warmth, pus, significant swelling, or fever

• Persistent or worsening skin symptoms that do not improve with basic self-care measures after one to two weeks

• Unexplained bruising or bleeding beyond what would be expected from a subcutaneous injection

If you are unsure whether your symptoms require urgent attention, NHS 111 can provide guidance.

Patients should also inform their clinician if they notice any new or unusual skin changes that appear unrelated to injection sites, as these may warrant dermatological review to exclude unrelated conditions.

If you are participating in a clinical trial, any adverse events — including skin reactions — should be reported directly to your study team through the trial's pharmacovigilance processes. For patients using retatrutide outside a clinical trial setting (for example, under an MHRA-approved access framework), suspected adverse reactions should be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Do not stop taking retatrutide without first speaking to your clinician or trial team, even if you are experiencing side effects. A clinician can help weigh the benefits and risks and may recommend a dose adjustment or a temporary pause in treatment if clinically appropriate.

MHRA Guidance and Current Safety Monitoring for Retatrutide

Retatrutide is not licensed in the UK; access is limited to approved clinical trials, and no EAMS designation has been granted, so adverse events must be reported through trial pharmacovigilance processes rather than Yellow Card.

Retatrutide is not currently licensed for use in the United Kingdom. It remains under clinical investigation, with Phase 3 trials ongoing at the time of writing. As such, the MHRA has not yet issued a Summary of Product Characteristics (SmPC) or specific product guidance for retatrutide.

Access in the UK is ordinarily limited to participation in an approved clinical trial. Outside of a clinical trial, access to an unlicensed investigational medicine such as retatrutide would only be possible under specific MHRA frameworks — for example, the Early Access to Medicines Scheme (EAMS), which requires a positive scientific opinion from the MHRA before use outside trials can be considered.^[8] No such EAMS designation has been granted for retatrutide at the time of writing. Supply via a 'specials' or named-patient route is not a routine or straightforward pathway for a new investigational agent of this kind and would require robust regulatory justification.

For investigational medicines used within clinical trials, safety data — including serious adverse events such as significant skin reactions — are collected and reviewed through the clinical trial framework. Trial sponsors are legally obligated to report serious adverse events to the MHRA in a timely manner, and the MHRA provides oversight of these processes.^[10]

The MHRA's Yellow Card scheme (yellowcard.mhra.gov.uk) is the primary mechanism through which healthcare professionals and patients in the UK can report suspected adverse drug reactions to licensed medicines. For retatrutide used within a clinical trial, adverse events should be reported through the trial sponsor's pharmacovigilance processes rather than via Yellow Card. If retatrutide were to be used under an approved MHRA access framework outside a trial, Yellow Card reporting would apply.

NICE has not yet issued guidance on retatrutide, as technology appraisal is contingent upon a medicine receiving a marketing authorisation. NICE's existing frameworks for evaluating obesity pharmacotherapies — including considerations of safety, efficacy, and cost-effectiveness — will likely apply when retatrutide is formally assessed.

Patients and clinicians are encouraged to monitor updates from the MHRA, EMA, and NICE as the evidence base for retatrutide continues to develop, and to rely on authoritative sources — including the MHRA website, NICE guidance, and peer-reviewed trial publications — rather than anecdotal reports when making treatment decisions.

Frequently Asked Questions